Law firm pursues Risperdal link to gynecomastia
Following research that indicates a possible link between gynecomastia and use of Risperdal, a law firm says it is continuing to offer legal consultations to those who developed the condition.
Researchers at the University of British Columbia examined health records for more than 82,000 men between 40 and 85 years old over a 10-year span. They found that around 16% of men exposed to risperidone developed gynecomastia within 60 days, according to results published in the Journal of Clinical Psychopharmacology last week.
“Our firm is representing a number of plaintiffs in Risperdal lawsuits that claim the drug caused gynecomastia. This report just adds to a growing body of evidence that supports the allegations put forth in these and other claims,” said Bernstein Liebhard LLP, a New-York based law firm, in a statement. The majority of claims are being pursued in mass tort litigation in Pennsylvania's Philadelphia Court of Common Pleas.
Risperdal, an antipsychotic medication that has been used off-label for long-term care residents with dementia, is designed to treat schizophrenia. Last year, the U.S. Department of Justice reached a $2.2 billion settlement with Johnson & Johnson and Janssen over the marketing of the medication.